GNFTF: AI 评分 73/100 — AI 分析 (4月 2026)

Genfit S.A. is a biopharmaceutical company focused on discovering and developing treatments for metabolic and liver diseases. Their lead product candidate, Elafibranor, is in Phase 3 clinical trials for primary biliary cholangitis.

Key Facts: AI Score: 73/100 Sector: Healthcare

公司概况

概要：

Genfit S.A. is a biopharmaceutical company specializing in metabolic and liver disease treatments, including Elafibranor for primary biliary cholangitis. With diagnostic solutions like NIS4 technology and partnerships with Labcorp and Genoscience Pharma, Genfit navigates the competitive biotech landscape, focusing on unmet needs in liver-related conditions.

GNFTF是做什么的？

Genfit S.A., established in 1999 and headquartered in Loos, France, is a biopharmaceutical company dedicated to discovering and developing innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases. The company's primary focus is on addressing significant unmet medical needs in areas such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and cholangiocarcinoma (CCA). Genfit's lead product candidate, Elafibranor, is currently in Phase 3 clinical development for the treatment of PBC. Additionally, the company is developing NIS4 technology for the diagnosis of NASH and fibrosis, aiming to provide a non-invasive diagnostic tool for early detection and monitoring of disease progression. Genfit is also advancing GNS561, a drug candidate in Phase 1b/2 trial for CCA, and Nitazoxanide, in Phase 1 trial for acute-on-chronic liver failure. Genfit has established strategic collaborations, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test, and with Genoscience Pharma for the development and commercialization of GNS561 for CCA. These partnerships underscore Genfit's commitment to expanding its reach and impact in the field of liver diseases.

GNFTF的投资论点是什么？

Genfit S.A. presents a focused investment opportunity within the biotechnology sector, driven by its pipeline of drug candidates targeting liver diseases. The Phase 3 clinical trial of Elafibranor for PBC represents a near-term catalyst, with potential for market approval and revenue generation. The development of NIS4 technology for NASH diagnosis offers a longer-term growth avenue, addressing the increasing prevalence of NASH globally. However, the company's negative profit margin of -85.9% and reliance on clinical trial outcomes pose significant risks. Successful commercialization of its products and strategic partnerships are crucial for achieving profitability and shareholder value. Investors should closely monitor clinical trial results, regulatory approvals, and competitive dynamics within the liver disease treatment market.

GNFTF在哪个行业运营？

Genfit S.A. operates within the competitive biotechnology industry, focusing on the development of treatments and diagnostics for liver diseases. The NASH market, in particular, is experiencing significant growth due to the increasing prevalence of obesity and related metabolic disorders. Key competitors include BRIBF, BXPHF, IPHYF, JWCTF, and MLLCF, each pursuing different approaches to address liver diseases. Genfit's strategic partnerships and focus on innovative diagnostic solutions position it to capture a share of this expanding market, estimated to reach billions of dollars in the coming years.

Biotechnology

Healthcare

GNFTF有哪些增长机遇？

Elafibranor for Primary Biliary Cholangitis (PBC): Elafibranor, currently in Phase 3 clinical trials, represents a significant growth opportunity for Genfit. If approved, Elafibranor could address a substantial unmet need in the treatment of PBC, a chronic liver disease. The PBC market is projected to grow, driven by increased awareness and improved diagnostic methods. Successful completion of Phase 3 trials and subsequent regulatory approval could lead to significant revenue generation for Genfit, potentially starting in late 2026 or early 2027.
NIS4 Technology for NASH Diagnosis: The development of NIS4 technology for the non-invasive diagnosis of NASH and fibrosis offers a compelling growth avenue. NASH is a rapidly growing liver disease, and early diagnosis is crucial for effective management. NIS4 aims to provide a convenient and accurate diagnostic tool, potentially capturing a significant share of the NASH diagnostics market. Commercialization of NIS4, potentially through partnerships, could contribute to Genfit's revenue growth starting in 2027.
GNS561 for Cholangiocarcinoma (CCA): Genfit's GNS561, currently in Phase 1b/2 trial for CCA, represents a longer-term growth opportunity. CCA is a rare but aggressive cancer of the bile ducts, with limited treatment options. Successful development and commercialization of GNS561 could address a critical unmet need and generate revenue for Genfit, although this is likely several years away, potentially 2029 or later.
Partnership with Labcorp for NASHnext: Genfit's licensing agreement with Labcorp for the commercialization of NASHnext provides a revenue stream and market access. NASHnext is a blood-based molecular diagnostic test for NASH. This partnership allows Genfit to leverage Labcorp's extensive network and expertise in diagnostics, accelerating the adoption of NASHnext and contributing to Genfit's financial performance. Revenue from this partnership is ongoing.
Expansion into New Therapeutic Areas: Genfit could explore expansion into new therapeutic areas within metabolic and liver diseases, leveraging its expertise and infrastructure. This could involve developing new drug candidates or acquiring existing assets. Expanding the pipeline would diversify Genfit's revenue streams and reduce its reliance on individual products. This is a longer-term strategy, potentially unfolding over the next 5-10 years.

Market capitalization of $0.54 billion reflects investor valuation of Genfit's pipeline and potential.
A P/E ratio of -11.22 indicates that the company is currently unprofitable, typical for biotechnology firms in the development stage.
Gross margin of 93.1% suggests strong potential profitability upon successful commercialization of its products.
Beta of 1.19 indicates that the stock is slightly more volatile than the market, reflecting the inherent risks in biotechnology investments.
The company's focus on liver diseases addresses a significant unmet medical need, driving potential for future growth.

GNFTF提供哪些产品和服务？

Discovers and develops drug candidates for metabolic diseases.
Focuses on treatments for liver-related diseases.
Develops diagnostic solutions for liver conditions.
Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Seeks regulatory approval for its products from health authorities.
Commercializes its products through partnerships and direct sales.

GNFTF如何赚钱？

Develops and patents novel drug candidates and diagnostic technologies.
Out-licenses or partners with other companies for commercialization.
Generates revenue through licensing fees, milestone payments, and royalties.
Potentially generates revenue through direct sales of diagnostic products.

Patients suffering from metabolic and liver diseases.
Physicians who treat patients with these conditions.
Diagnostic laboratories that use Genfit's diagnostic products.
Pharmaceutical companies that partner with Genfit for drug development and commercialization.

Proprietary drug candidates and diagnostic technologies protected by patents.
Expertise in metabolic and liver diseases.
Established partnerships with leading pharmaceutical and diagnostic companies.
Clinical trial data demonstrating the efficacy and safety of its products.

什么因素可能推动GNFTF股价上涨？

Upcoming: Results from Phase 3 clinical trial of Elafibranor for PBC expected in late 2026 or early 2027.
Ongoing: Commercialization of NASHnext through partnership with Labcorp.
Upcoming: Potential regulatory approval of Elafibranor for PBC in late 2027, if Phase 3 results are positive.
Ongoing: Development of NIS4 technology for NASH diagnosis.
Upcoming: Advancement of GNS561 through Phase 1b/2 trial for CCA with potential data release in 2027.

GNFTF的主要风险是什么？

Potential: Failure of Elafibranor in Phase 3 clinical trials.
Potential: Regulatory hurdles in obtaining approval for Elafibranor.
Ongoing: Competition from other companies developing treatments for liver diseases.
Ongoing: Dependence on partnerships for commercialization.
Potential: Patent expiration on key technologies.

GNFTF的核心优势是什么？

Proprietary drug candidates in clinical development.
Strong expertise in metabolic and liver diseases.
Strategic partnerships with leading companies.
Innovative diagnostic technologies.

GNFTF的劣势是什么？

High reliance on clinical trial outcomes.
Negative profitability.
Limited commercial infrastructure.
Dependence on partnerships for commercialization.

GNFTF有哪些机遇？

Growing market for NASH treatments and diagnostics.
Expansion into new therapeutic areas.
Potential for regulatory approval of Elafibranor.
Increased adoption of NIS4 technology.

GNFTF面临哪些威胁？

Competition from other pharmaceutical and biotechnology companies.
Clinical trial failures.
Regulatory hurdles.
Patent expiration.

GNFTF的竞争对手是谁？

Bristol-Myers Squibb — Major pharmaceutical company with a broad portfolio, including liver disease treatments. — (BRIBF)
Boehringer Ingelheim — Focuses on various therapeutic areas, including metabolic diseases. — (BXPHF)
Inventiva — Develops therapies for NASH and other metabolic diseases. — (IPHYF)
JW Pharmaceutical — Korean pharmaceutical company with a diverse portfolio. — (JWCTF)
Mallinckrodt PLC — Specialty pharmaceutical company with a focus on autoimmune and rare diseases. — (MLLCF)

Key Metrics

MoonshotScore: 73/100

Company Profile

CEO: Pascal Prigent
Headquarters: Loos, FR
Employees: 180
Founded: 2014

AI Insight

AI analysis pending for GNFTF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Genfit S.A. do?

Genfit S.A. is a biopharmaceutical company focused on developing treatments and diagnostic solutions for metabolic and liver-related diseases. Their lead product candidate, Elafibranor, is in Phase 3 clinical trials for primary biliary cholangitis (PBC). The company also develops NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Genfit partners with companies like Labcorp to commercialize diagnostic tests, aiming to address unmet needs in the diagnosis and treatment of liver diseases.

What do analysts say about GNFTF stock?

AI analysis is pending for GNFTF stock. Generally, biotechnology stocks are evaluated based on their clinical pipeline, potential market size for their drugs, and financial runway. Investors should monitor clinical trial results, regulatory milestones, and competitive dynamics. Valuation metrics often include discounted cash flow analysis, considering the potential revenue from successful drug commercialization. Due to the OTC listing, analyst coverage may be limited, requiring investors to conduct thorough independent research.

What are the main risks for GNFTF?

The primary risks for Genfit S.A. include the potential failure of Elafibranor in Phase 3 clinical trials, which would significantly impact the company's value. Regulatory hurdles in obtaining approval for Elafibranor also pose a risk. Competition from other companies developing treatments for liver diseases, such as NASH and PBC, is an ongoing challenge. The company's reliance on partnerships for commercialization and potential patent expiration on key technologies represent additional risks. Furthermore, the OTC listing introduces liquidity and transparency concerns.

How does Genfit S.A. manage patent expiration risks?

Genfit S.A. manages patent expiration risks through a multi-faceted approach. This includes continuously innovating to develop new drug candidates and diagnostic technologies, extending patent protection through formulation and process patents, and strategically licensing intellectual property. The company also focuses on building a strong portfolio of patents around its core technologies to create barriers to entry for competitors. Furthermore, Genfit actively monitors the competitive landscape and takes legal action when necessary to protect its intellectual property rights.

What is Genfit S.A.'s drug pipeline status?

Genfit S.A.'s drug pipeline includes Elafibranor, currently in Phase 3 clinical trials for primary biliary cholangitis (PBC). GNS561 is in Phase 1b/2 trial for cholangiocarcinoma (CCA), and Nitazoxanide is in Phase 1 trial for acute-on-chronic liver failure. The pipeline also includes NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Key therapeutic areas include PBC, NASH, CCA, and acute-on-chronic liver failure. Upcoming catalysts include the results from the Phase 3 trial of Elafibranor and the advancement of GNS561 through clinical trials.